<DOC>
	<DOC>NCT01345734</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.</brief_summary>
	<brief_title>Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects with type 2 diabetes mellitus, including newlydiagnosed subjects or those already receiving other antidiabetic medications including GLP1 analogues other than Liraglutide, who require treatment with liraglutide according to the clinical judgment of their treating physician Subjects who are capable of giving studyspecific signed informed consent before any collection of information Subjects with type 1 diabetes Subjects who are or have previously been on liraglutide Subjects who are participating in another clinical trial Subjects with a hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections) Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the following 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>